サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Menopausal Disorders Drug Development Pipeline Review, 2018Pipeline Review, 2018

更年期障害薬剤開発パイプラインレビュー2018

レポート概要

本レポートは、更年期障害のパイプラインの状況と、閉経後骨粗鬆症、膣萎縮、および更年期の血管運動症状に対して開発中の薬剤、また薬剤開発に関わる主要企業に関する包括的な情報を提供します。また、休止中の製品や中止製品も含みます。

閉経後骨粗鬆症は骨粗鬆症の最も一般的な形態であり、閉経後の多くの女性に影響を与えます。症状には、背部痛、身長低下、または前屈姿勢のような脊柱の変形が含まれます。危険因子には、年齢、性別、家族歴、骨構造および体重が含まれます。この適応症の開発には20の製品があります。

膣萎縮は、エストロゲンの少ない体に起因する膣壁の菲薄化、乾燥および炎症です。兆候と症状には、膣の乾燥、膣分泌物、性器のかゆみ、排尿による灼熱感、尿意切迫、尿路感染症および尿失禁が含まれます。危険因子には喫煙が含まれます。喫煙は血液循環を妨げ、膣や他の組織の酸素を奪います。組織が薄くなることは、血流が減少または制限されるところで起こります。この適応症の開発には5つの製品があります。

更年期の血管運動症状には、閉経期および閉経周辺期のホルモン変動に起因する、皮膚に近い血管の突然の開口部に起因する一過性熱感または寝汗が含まれます。これらの症状は、いくつかの薬物療法、エストロゲン枯渇、甲状腺疾患、糖尿病、多汗症、不安症およびパニック障害、肥満、ホルモン産生腫瘍、慢性感染症および神経障害により引き起こされます。この適応症の開発には12の製品があります。

更年期障害のために開発中の製品により作用する分子標的には、腫瘍壊死因子リガンドスーパーファミリーメンバー11、副甲状腺ホルモン受容体およびプロゲステロン受容体が含まれます。このパイプライン領域で活動する企業には、Amgen、TherapeuticsMD、Ipsenなどがあります。

■調査範囲

  • 各パイプライン内において、最も活発に活動しているのはどの企業でしょうか?
  • 各適応症において、各開発段階で最も優れた薬物療法的アプローチはどれでしょうか?
  • このパイプライン内において、大学や組織は製薬企業と比べてどの程度重要な役割を果たすでしょうか?
  • この疾患分野において起きた最も重要なR&Dの画期的出来事や、データの公表は何でしょうか?

レポート詳細

目次

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Menopausal Disorders Report Coverage
2.2 Post Menopausal Osteoporosis - Overview
2.3 Vaginal Atrophy (Atrophic Vaginitis) - Overview
2.4 Vasomotor Symptoms of Menopause (Hot Flashes) - Overview

3 Therapeutics Development
3.1 Post Menopausal Osteoporosis
3.2 Vaginal Atrophy (Atrophic Vaginitis)
3.3 Vasomotor Symptoms of Menopause (Hot Flashes)

4 Therapeutics Assessment
4.1 Post Menopausal Osteoporosis
4.2 Vaginal Atrophy (Atrophic Vaginitis)
4.3 Vasomotor Symptoms of Menopause (Hot Flashes)

5 Companies Involved in Therapeutics Development
5.1 Post Menopausal Osteoporosis
5.2 Vaginal Atrophy (Atrophic Vaginitis)
5.3 Vasomotor Symptoms of Menopause (Hot Flashes)

6 Dormant Projects
6.1 Post Menopausal Osteoporosis
6.2 Vaginal Atrophy (Atrophic Vaginitis)
6.3 Vasomotor Symptoms of Menopause (Hot Flashes)

7 Discontinued Products
7.1 Post Menopausal Osteoporosis
7.2 Vasomotor Symptoms of Menopause (Hot Flashes)

8 Product Development Milestones
8.1 Post Menopausal Osteoporosis
8.2 Vaginal Atrophy (Atrophic Vaginitis)
8.3 Vasomotor Symptoms of Menopause (Hot Flashes)

9 Appendix
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer

1.1 List of Tables
Table 1: Number of Products under Development for Post Menopausal Osteoporosis
Table 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis
Table 3: Products under Development by Companies, Post Menopausal Osteoporosis
Table 4: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis)
Table 5: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis)
Table 6: Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis)
Table 7: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes)
Table 8: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 9: Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 10: Number of Products by Stage and Target, Post Menopausal Osteoporosis
Table 11: Number of Products by Stage and Mechanism of Action, Post Menopausal Osteoporosis
Table 12: Number of Products by Stage and Route of Administration, Post Menopausal Osteoporosis
Table 13: Number of Products by Stage and Molecule Type, Post Menopausal Osteoporosis
Table 14: Number of Products by Stage and Target, Vaginal Atrophy (Atrophic Vaginitis)
Table 15: Number of Products by Stage and Mechanism of Action, Vaginal Atrophy (Atrophic Vaginitis)
Table 16: Number of Products by Stage and Route of Administration, Vaginal Atrophy (Atrophic Vaginitis)
Table 17: Number of Products by Stage and Molecule Type, Vaginal Atrophy (Atrophic Vaginitis)
Table 18: Number of Products by Stage and Target, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 19: Number of Products by Stage and Mechanism of Action, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 20: Number of Products by Stage and Route of Administration, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 21: Number of Products by Stage and Molecule Type, Vasomotor Symptoms of Menopause (Hot Flashes)
Table 22: Post Menopausal Osteoporosis - Pipeline by Amgen Inc,
Table 23: Post Menopausal Osteoporosis - Pipeline by Enteris BioPharma Inc,
Table 24: Post Menopausal Osteoporosis - Pipeline by GL Pharm Tech Corp,
Table 25: Post Menopausal Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd,
Table 26: Post Menopausal Osteoporosis - Pipeline by Ipsen SA,
Table 27: Post Menopausal Osteoporosis - Pipeline by Lupin Ltd,
Table 28: Post Menopausal Osteoporosis - Pipeline by Luye Pharma Group Ltd,
Table 29: Post Menopausal Osteoporosis - Pipeline by NIBEC,
Table 30: Post Menopausal Osteoporosis - Pipeline by Oncobiologics Inc,
Table 31: Post Menopausal Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy,
Table 32: Post Menopausal Osteoporosis - Pipeline by Uni-Bio Science Group Ltd,
Table 33: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals Inc,
Table 34: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Medinova AG,
Table 35: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals SA,
Table 36: Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD Inc,
Table 37: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by EndoCeutics Inc,
Table 38: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by MenoGeniX Inc,
Table 39: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Mithra Pharmaceuticals SA,
Table 40: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Ogeda SA,
Table 41: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by Pherin Pharmaceuticals Inc,
Table 42: Vasomotor Symptoms of Menopause (Hot Flashes) - Pipeline by TherapeuticsMD Inc,
Table 43: Post Menopausal Osteoporosis - Dormant Projects,
Table 44: Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects,
Table 45: Vasomotor Symptoms of Menopause (Hot Flashes) - Dormant Projects,
Table 46: Post Menopausal Osteoporosis - Discontinued Products,
Table 47: Vasomotor Symptoms of Menopause (Hot Flashes) - Discontinued Products,

1.2 List of Figures
Figure 1: Number of Products under Development for Post Menopausal Osteoporosis
Figure 2: Number of Products under Development by Companies, Post Menopausal Osteoporosis
Figure 3: Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis)
Figure 4: Number of Products under Development by Companies, Vaginal Atrophy (Atrophic Vaginitis)
Figure 5: Number of Products under Development for Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 6: Number of Products under Development by Companies, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 7: Number of Products by Targets, Post Menopausal Osteoporosis
Figure 8: Number of Products by Stage and Targets, Post Menopausal Osteoporosis
Figure 9: Number of Products by Mechanism of Actions, Post Menopausal Osteoporosis
Figure 10: Number of Products by Stage and Mechanism of Actions, Post Menopausal Osteoporosis
Figure 11: Number of Products by Routes of Administration, Post Menopausal Osteoporosis
Figure 12: Number of Products by Stage and Routes of Administration, Post Menopausal Osteoporosis
Figure 13: Number of Products by Molecule Types, Post Menopausal Osteoporosis
Figure 14: Number of Products by Stage and Molecule Types, Post Menopausal Osteoporosis
Figure 15: Number of Products by Targets, Vaginal Atrophy (Atrophic Vaginitis)
Figure 16: Number of Products by Stage and Targets, Vaginal Atrophy (Atrophic Vaginitis)
Figure 17: Number of Products by Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis)
Figure 18: Number of Products by Stage and Mechanism of Actions, Vaginal Atrophy (Atrophic Vaginitis)
Figure 19: Number of Products by Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis)
Figure 20: Number of Products by Stage and Routes of Administration, Vaginal Atrophy (Atrophic Vaginitis)
Figure 21: Number of Products by Stage and Molecule Types, Vaginal Atrophy (Atrophic Vaginitis)
Figure 22: Number of Products by Targets, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 23: Number of Products by Stage and Targets, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 24: Number of Products by Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 25: Number of Products by Stage and Mechanism of Actions, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 26: Number of Products by Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 27: Number of Products by Stage and Routes of Administration, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 28: Number of Products by Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes)
Figure 29: Number of Products by Stage and Molecule Types, Vasomotor Symptoms of Menopause (Hot Flashes)

発刊日

2018/06/29

体裁

PDF / 84ページ

販売価格

3,995USD

発行

GBI Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE